Deals of the day-Mergers and acquisitions
Adds: CVS, Frasers Group, Tetragon,
Oct 11 (Reuters) -The following bids, mergers, acquisitions and disposals were reported by 2000GMT on Friday:
** CVS Health CVS.N is exiting its core infusion services business and plans to either close or sell 29 related regional pharmacies in the coming months, a company spokesperson confirmed to Reuters on Friday. nL1N3LN0ZJ
** British sportswear and apparel retailer Frasers Group FRAS.L revised its takeover bid for Mulberry MUL.L to 150 pence per share on Friday, valuing the company at 111 million pounds ($145.11 million). nL4N3LN1H4
** Saudi Arabia's Public Investment Fund is not currently in talks to buy a stake in DAZN, the sports-streaming group backed by billionaire Len Blavatnik, PIF said in a statement on Friday. nL8N3LN1NM
** Investment group Tetragon TFG.AS is looking at options for British infrastructure investor Equitix, including a possible sale, two people with knowledge of the matter said, potentially adding to a rush of deals by funds in alternative assets. nL8N3LN0MG
** Nippon Steel 5401.T said it will sell its entire 50% stake in a joint-venture steel plant it has in Calvert, Alabama, with ArcelorMittal MT.LU, if the top Japanese steelmaker succeeds in a buyout bid for United States Steel X.N.
nL1N3LN07I
** Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said.
nL1N3LN07L
** Italy's Brembo BRBI.MI said it had agreed to buy suspension technology manufacturer Ohlins Racing for $405 million, in the premium brake maker's biggest ever acquisition.
nL1N3LN05Z
** British holiday group Saga SAGA.L said that Ageas AGES.BR would buy its insurance underwriting business for 67.5 million pounds ($88.1 million), and that it was in exclusive talks to set up a 20-year partnership for motor and home insurance with the Belgian firm.
nL4N3LN0HC
** Singapore-headquartered private healthcare company Health Management International, or HMI Medical, said it is acquiring a majority stake in Advanced Urology Associates, the largest private urology specialist group in the country.
nL1N3LN02B
** U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's NOVOb.CO controlling shareholder would acquire contract drug manufacturer Catalent CTLT.N, saying it may give the pharmaceutical company an unlawful advantage in obesity drugs.
nL1N3LM0LD
(Compiled by Rajarshi Roy, Puyaan Singh and Jaiveer Shekhawat in Bengaluru)
</body></html>Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
